Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2026.083902
Journal Menu
Special Issues
Table of Content

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

REVIEW

Nuclear–Cytoplasmic Axis in Cancer: From Protein Mislocalization to Anticancer Drug Resistance

Xueping Zhu1,2,3,#, Misi He1,2,3,#, Ling Wang1,2,3,#, Rui Su4, Lin Zhong1,2,3, Ting Guo1,2,3,4, Haixia Wang1,2,3,*, Dongling Zou1,2,3,*
1 Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing Cancer Institute, Chongqing Cancer Hospital, Chongqing, China
2 Chongqing Specialized Medical Research Center of Ovarian Cancer, Chongqing, China
3 Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China
4 Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, USA
* Corresponding Author: Haixia Wang. Email: email; Dongling Zou. Email: email
# These authors contributed equally to this work
(This article belongs to the Special Issue: Molecular Targeting Therapy for Anticancer Treatment)

Oncology Research https://doi.org/10.32604/or.2026.083902

Received 13 April 2026; Accepted 11 June 2026; Published online 07 July 2026

Abstract

Nucleocytoplasmic transport (NCT) regulates the spatial distribution of proteins and RNA between the nucleus and cytoplasm. NCT dysregulation can mislocalize tumor suppressors, DNA-repair factors, transcription factors, and drug targets in cancer. In this review, we conceptualize NCT-dependent protein mislocalization as a spatial regulatory framework for anticancer drug resistance, rather than as a catalogue of transport components. We systematically discuss how nuclear pore complex (NPC) remodeling, transport-receptor imbalance, post-translational modification (PTM)-regulated cargo routing, signaling-NCT crosstalk, nuclear localization signal/nuclear export signal (NLS/NES) alterations, and tumor microenvironmental pressures jointly drive aberrant nucleocytoplasmic distribution. These processes can further regulate apoptosis, DNA-damage repair, oncogenic transcription, oxidative stress adaptation and drug-target accessibility, which ultimately promote drug tolerance and therapeutic resistance. We further distinguish clinically validated mechanisms from preclinical phenotypes and correlative observations. At present, the most advanced therapeutic evidence mainly supports exportin 1/chromosome region maintenance 1 (XPO1/CRM1) inhibition, particularly selinexor in selected hematologic malignancies; in contrast, strategies targeting the NPC, importins, PTM pathways, microenvironmental cues, or localization signals remain largely investigational. By integrating mechanistic, preclinical, translational, and clinical evidence, this review aims to synthesize current evidence on NCT-dependent protein mislocalization as a resistance-relevant axis and to highlight the need for cargo-specific biomarkers and rational combination strategies to translate this biology into anticancer therapy.

Keywords

Nucleocytoplasmic transport; nuclear pore complex; transport receptors; anticancer drug resistance; post-translational modifications; tumor microenvironment; nuclear localization signal mutations; nuclear export signal mutations

  • 140

    View

  • 22

    Download

  • 0

    Like

Related articles
Copyright© 2026 Tech Science Press
© 1997-2026 TSP (Henderson, USA) unless otherwise stated

Share Link